Citations

Showing 10 of 108152 citations.

Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025
Voorhees, Peter M. , Jakubowiak, Andrzej J., Kumar, Shaji K., Kanapuru, Bindu, Baines, Andrea C. , Bhatnagar, Vishal, Ershler, Rachel, Theoret, Marc R., Gormley, Nicole J., Pazdur, Richard, Gormley, Nicole , Voorhees, Peter , Gormley, Nicole , Jakubowiak, Andrzej J., Kumar, Shaji K., Kanapuru, Bindu, Baines, Andrea C. , Bhatnagar, Vishal, Ershler, Rachel, Theoret, Marc R., Pazdur, Richard

Mayo Clinic

Clinical Cancer Research | July 27, 2021 | Volume: 28 | Issue: 1 | Pages: 23-26

10.1158/1078-0432.ccr-21-1069 | PMID 34315721 Get It

Abstract The multiple myeloma treatment landscape has evolved considerably over the last 20 years with the development of multiple therapies with novel mechanisms of action and new combination regimens. However, the recent failure of several large phase III trials, coupled with an increased understanding of the mutational landscape of multiple myeloma has provided opportunities to explore optimal strategies for future multiple myeloma drug development. The Office of Oncologic Diseases at the FDA held an educational symposium, “Drug Development in MM-Project 2025,” in November 2019. The symposium brought together select U.S.-based academic thought leaders in the field of multiple myeloma to explore issues relevant to regulatory science in the field, including considerations for trial design, combination strategies, control arms, and precision medicine. This article summarizes the highlights of this educational symposium held at the FDA, including discussions on the future development of novel drugs and drug combinations and biomarker-directed therapies for patients with multiple myeloma.
Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID‐19: A multi‐center retrospective cohort study
Li, X J , Meng, Yu , Yin, Haiyan , Gao, Wenyong , Yang, Xiao , Xu, Dian‐Shuang, Cai, Xingdong , Guan, Yin, Lerman, Lilach O. , Peng, Zhiyong , Zhou, Hourong, Li, Xia-Qing , Liu, Han

Mayo Clinic

Journal of Medical Virology | July 27, 2021 | Volume: 93 | Issue: 12 | Pages: 6641-6652

10.1002/jmv.27234 | PMID 34314040 Get It

AbstractAcute kidney injury (AKI) may develop in patients with coronavirus disease 2019 (COVID‐19) and is associated with in‐hospital death. We investigated the incidence of AKI in 223 hospitalized COVID‐19 patients and analyzed the influence factors of AKI. The incidence of cytokine storm syndrome and its correlation with other clinicopathologic variables were also investigated. We retrospectively enrolled adult patients with virologically confirmed COVID‐19 who were hospitalized at three hospitals in Wuhan and Guizhou, China between February 13, 2020, and April 8, 2020. We included 124 patients with moderate COVID‐19 and 99 with severe COVID‐19. AKI was present in 35 (15.7%) patients. The incidence of AKI was 30.3% for severe COVID‐19 and 4.0% for moderate COVID‐19 (p < 0.001). Furthermore, cytokine storm was found in 30 (13.5%) patients and only found in the severe group. Kidney injury at admission (odds ratio [OR]: 3.132, 95% confidence interval [CI]: 1.150–8.527; p = 0.025), cytokine storm (OR: 4.234, 95% CI: 1.361–13.171; p = 0.013), and acute respiratory distress syndrome (ARDS) (OR: 7.684, 95% CI: 2.622–22.523; p < 0.001) were influence factors of AKI. Seventeen (48.6%) patients who received invasive mechanical ventilation developed AKI, of whom 64.7% (11/17) died. Up to 86.7% of AKI patients with cytokine storms may develop a secondary bacterial infection. The leukocyte counts were significantly higher in AKI patients with cytokine storm than in those without (13.0 × 10⁹/L, interquartile range [IQR] 11.3 vs. 8.3 × 10⁹/L, IQR 7.5, p = 0.005). Approximately 1/6 patients with COVID‐19 eventually develop AKI. Kidney injury at admission, cytokine storm and ARDS are influence factors of AKI. Cytokine storm and secondary bacterial infections may be responsible for AKI development in COVID‐19 patients.
A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014–2019
Puri, Pranav , Cortese, Denis A., Baliga, Sujith , Cortese, Denis, Puri, P

Mayo Clinic

Journal of Dermatological Treatment | July 27, 2021 | Volume: 33 | Issue: 4 | Pages: 2004-2007

10.1080/09546634.2021.1962002 | PMID 34314297 Get It

Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma
Bhindi, Bimal , Bearrick, Elizabeth , Cheville, John C. , Lohse, Christine M. , Mason, Ross , Shah, Paras , Harrington, Susan M. , Boorjian, Stephen A. , Thompson, R. Houston, Leibovich, Bradley C. , Zhang, Henan , Dong, Haidong

Mayo Clinic

Kidney Cancer | July 27, 2021 | Volume: 5 | Issue: 3 | Pages: 129-135

10.3233/kca-210116 Get It

BACKGROUND: Bim (BCL-2-interacting mediator of cell death) is a downstream pro-apoptotic signaling molecule activated by the PD-1 pathway. OBJECTIVE: We sought to determine if Bim expression in peritumoral T-lymphocytes (PTLs) is associated with survival in patients with metastatic clear cell renal cell carcinoma (ccRCC). METHODS: Immunohistochemistry staining for Bim was performed on paraffin-embedded tumor tissue blocks from patients with metastatic ccRCC who underwent nephrectomy between 1990-2004. Associations of Bim expression with cancer-specific survival (CSS) and overall survival (OS) from date of metastasis were evaluated using multivariable Cox regression models, adjusting for age, sex, and metastases-score. RESULTS: 525 patients with metastatic ccRCC, of whom 169 (32%) had metastases at time of nephrectomy were studied. After multivariable adjustment, high Bim expression remained associated with worse CSS (HR = 1.31; 95% CI 1.07–1.59; p = 0.008) and OS (HR = 1.28; 95% CI 1.06–1.55; p = 0.01). The interaction between Bim and PD-L1 was not statistically significant for CSS ( p = 0.68) or OS ( p = 0.57), suggesting that the associations between Bim and survival outcomes were not significantly different based on tumor PD-L1 expression. CONCLUSION: High Bim expression in PTLs at nephrectomy is prognostic of worse CSS and OS in patients with metastatic ccRCC, irrespective of tumor PD-L1 expression. The role of earlier PD-1/PD-L1-directed therapy warrants evaluation in these patients.
Opioid-Sparing Analgesic Effects of Peripheral Nerve Blocks in Percutaneous Nephrolithotomy: A Systematic Review
Winoker, Jared S. , Koo, Kevin , Matlaga, Brian R., Alam, Ridwan

Mayo Clinic

Journal of Endourology | July 27, 2021 | Volume: 36 | Issue: 1 | Pages: 38-46

10.1089/end.2021.0402 | PMID 34314232 Get It

Introduction: Multimodal analgesic regimens incorporating peripheral nerve blocks (PNBs) have demonstrated reduced postoperative pain, opioid use, and recovery time in various disease states. However, this remains a subject of limited investigation in the percutaneous nephrolithotomy (PCNL) domain. In the face of an ongoing opioid epidemic and collective push to enhance prescribing stewardship, we sought to examine the potential opioid-sparing effect of PNBs in PCNL. Methods: A systematic review of Embase and PubMed was performed to identify all randomized controlled trials evaluating the use of a PNB with general anesthesia (GA) vs GA alone for pain control following PCNL. Studies evaluating neuraxial (epidural and spinal) anesthesia and those without GA as the control arm were excluded. Results: Seventeen trials evaluating 1,012 procedures were included. Five different blocks were identified and evaluated: paravertebral ( n = 8), intercostal nerve ( n = 3), quadratus lumborum ( n = 2), transversus abdominis plane ( n = 1), and erector spinae ( n = 3). Nine of 16 (56%) studies observed lower pain scores with PNB use throughout the 24-hour postop period. By comparison, improved pain scores with PNBs were limited to the early (<6 hours) recovery period in five studies and two found no difference. Total analgesic and opioid requirements were significantly higher in the GA control arm in nearly all studies (12/14, 86%). Operative times were similar and there were no differences in rates of intercostal access or nephrostomy tube insertion between study arms in any trial. Conclusions: While greater analgesic use with GA alone likely minimizes or obscures differences in patient-reported pain scores, PNBs may offer a significant opioid-sparing analgesic effect during postoperative recovery after PCNL.
QS10: TOWARD AN OBJECTIVE OUTCOME IN FACIAL REJUVENATION SURGERY: AN EYETRACKING STUDY
Boonipat, Thanapoom , Muro, Jose, Hebel, Nathan , Lin, Jason , Bite, Uldis, Stotland, Mitchell A. , Muro, Jose

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 49-50

10.1097/01.gox.0000770196.47411.22 Get It

Purpose: The availability of an objective outcome measure for facial reconstructive surgery remains elusive. Evaluations submitted by external raters or by patient self-report are subjective, and may unreliably convey how one is perceived by others. We are interested in observers’ instantaneous responses to the human face. The goal of modern facelift and associated procedures for facial rejuvenation are to achieved subtle differences that lead to the perception of youth and attractiveness, yet the observer cannot pinpoint what exactly have been done to the patient’s face. We explored the visual markers that lead to differential perception of patients before and after facial rejuvenation surgery (high SMAS facelift, neck lift, fat grafting, brow lifts and blepharoplasty). Methods: 40 images were obtained which portrayed pre and post operative photos of patients who underwent high SMAS facelift, fat grafting, and browlifts and blepharoplasty for facial rejuvenation. Photographs were obtained before and after surgical correction (>3 months postop). 40 observers examined the images while an infrared eye-tracking camera recorded their eye movements. The observers were then asked to rate the image for character attributes (attractiveness, trustworthiness, sociability, healthy, and capability, 1-7 scale, and also estimate the age of the patient). Results: (i) The surgical intervention was found to decrease observers’ attention to the cervical region, but did not change how other areas are perceived significantly.(ii) The surgical intervention was found to significantly increase the character ratings for all five attributes compared to pre op controls: (sociable 3.53 to 4.18, trustworthy 3.85 to 4.20, attractive 3.34 to 3.3.90, health 4.07 to 4.61, capable 3.91 to 4.43.(iii) Average age estimate of the photos decreased significantly from 54 years (SD 6) to 48.6 years (SD 5.2), with true average age of 57.4 (7.6). Conclusion: We provide data illustrating a novel and objective technique to evaluate the effect of reconstructive intervention for facial rejuvenation. Consistent with the goals of subtle facial rejuvenation, the observers did not detect any particular areas of difference post operatively, but gain a more favorable impression of the person, and also perceived them as younger by a decade compared to their true age.
QS1: Nasopharyngeal Airway and Subcranial Space Analysis in Pfeiffer Syndrome
Alperovich, Michael , Persing, John A. , Lu, Xiaona , Forte, Antonio J. , Tonello, Cristiano , Alonso, Nivaldo

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 25-26

10.1097/01.gox.0000770060.46416.97 Get It

Background: Tracheotomy in infancy helps patients with Pfeiffer syndrome survive by preventing respiratory crisis, however, difficulty in decannulation consequently may be a challenge. This study attempts to investigate the regional abnormalities of the nasopharyngeal airway in Pfeiffer syndrome, to provide an anatomic basis for the upper airway surgical treatment and decannulation. Method: Seventy-two preoperative CT scans (Pfeiffer syndrome, n=30; control, n=42) were included in this study. The airway volume, cross-sectional area, and cephalometrics, were measured using Materialise software. Results: Patients with Pfeiffer syndrome developed a 50% (p<0.001) reduction of nasal airway volume, and a 44% (p=0.003) restriction in pharyngeal airway volume. The cross-sectional area of Pfeiffer patients at the choana, was only half that of normals’ (p<0.001). The posterior width of nasal airway in Pfeiffer syndrome was shortened by 13% (p=0.003), and the height was reduced by 21% (p<0.001). The cross-sectional areas at condylion and gonion levels, indicating the caliber of pharyngeal airway at entrance and midsection, were reduced by 67% (p<0.001) and 47% (p<0.001), respectively, when compared with normals. Conclusion: Nasal airway volume in Pfeiffer syndrome is significantly restricted, in length, height and width, along with the choanal stenosis in all cases in this cohort. The reduced anteroposterior length of nasal airway contributes to the shortened maxilla, more than the anteroposterior position. The limited nasal pathway height and width results from the hypoplastic sphenoid. Mediolateral and anteroposterior restricted dimensions are evident across the entire course of pharyngeal airway. Therefore, mediolateral maxillary expansion likely benefits Pfeiffer syndrome patients, in addition to maxillomandibular advancement.
5: Correlation Of Face Transplant Smile Excursion Measurements With Emotional Evaluation By Artificial Intelligence
Hebel, Nathan SD, Boonipat, Thanapoom , Lin, Jason , Hebel, Nathan , Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 32-32

10.1097/01.gox.0000770100.77689.90 Get It

Purpose: Examining the outcomes and progression of face transplants has expanded to include the recent advancements in artificial intelligence. This novel methodology has allowed for the objective exploration of emotional expression. To our knowledge, this examined emotional expression has yet to be correlated to the hypothesized functioning of the allograft. We have combined the result of the AI software with a software analyzing smile excursion; demonstrating the progression of the allograft in our face transplant patient. This study helps illuminate the software possibilities for objective measures in transplant progression. Methods: Images were analyzed from our face transplant patient post-operatively at approximately 6-month intervals for four years. The still images for each time interval include both a neutral facial expression and a full-face smile with teeth. The images were taken from video clips of the patient and then analyzed using the FACEgram software (Hadlock & Urban, 2012). The measurements of the smile excursion were standardized based off of the pupil diameter and excursion was measured relative to the neutral expression of each time period. The emotional expression data was acquired using FaceReader AI software from Noldus Information Technology (Wageningen, The Netherlands). The emotional analysis was done on 2 second clips from clinical videos of the patient, the same videos used for the still images. This data was correlated with the smile excursion measurements. Results: The post-operative smile excursion analysis from 6 to 49 months demonstrated a near double in smile excursion from 3.58mm to 6.04mm. The smile excursion data has a squared correlation of 0.705; a strong upward linear trend of excursion. From 6 to 35 months, the happy emotion increased gradually from 0% to 15.8% (49-month data unavailable). Performed correlative analysis showed a positive correlation coefficient of 0.63. This moderate to strong correlation demonstrates the intuitive relationship of happy emotion and lip excursion during full face smiling. The findings also substantiate the AI software’s detection of increasing activity in the lip corner puller action unit from zero to 3/5 intensity over the same period. Conclusion: This study demonstrates the correlation of smile excursion to happy emotional expression in our face transplant patient. The correlation square of the lip excursion shows a trend of increased functioning of the allograft over time; substantiating the AI’s finding. This data provides evidence for the use of artificial intelligence as a measure of transplant strength progression. The conjoined analysis of patient images and videos has supported proof for the ability to analyze transplant healing progression and efficacy in an objective form. Hadlock, T. A., & Urban, L. S. (2012). Toward a Universal, Automated Facial Measurement Tool in Facial Reanimation. Archives of Facial Plastic Surgery,14(4). doi:10.1001/archfacial.2012.111
QS5: The Effect of Stem Cells and Local Tacrolimus on Neurite Extension
Saffari, Tiam M. , Chan, Katelyn, Saffari, Sara , Chan, Katelyn, Borschel, Gregory Howard , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 19-19

10.1097/01.gox.0000770024.35327.48 Get It

Purpose: Application of mesenchymal stem cells (MSCs) or tacrolimus (FK506), an FDA approved immunosuppressant, to nerve grafts has been a topic of interest to enhance peripheral nerve regeneration. The aim of this study was to investigate the combined effect of MSCs and local delivery of FK506 on nerve regeneration when applied to nerve autografts and decellularized nerve allografts. Methods: A three-dimensional (3D) in vitro compartmented cell culture system, validated by Tajdaran et al (2019), consisted of rat neonatal dorsal root ganglion (DRG) adjacent to rat nerve autograft or decellularized allograft. This model was used to evaluate regenerating neurites from the DRG into the peripheral nerve scaffold. Nerve autografts and decellularized allografts were augmented with (i) dynamic undifferentiated MSC seeding, (ii) local application of FK506 (100 ng/mL) or (iii) both (N=9/group). Local application was ensured by isolating the central system (i.e. DRG side) from the peripheral system (i.e. nerve graft side), where treatment was applied. After 48-hours of incubation, DRG-nerve graft constructs were collected, fixed, sectioned and stained against neurofilament-160 to measure neurite extension. CD90 staining was used to confirm stem cell characterization. Results: All grafts treated with MSCs confirmed CD90 expression. Compared to untreated autografts, neurite extension in autografts treated with FK506 and autografts treated with MSCs and FK506 combined were found superior (P<0.001 and P=0.0001, respectively), and comparable to autografts treated with MSCs (P=0.12). Compared to untreated allografts, allografts treated with FK506, and allografts treated with MSCs and FK506 were found superior (P<0.001 and P=0.0001, respectively), and allografts treated with MSCs were found comparable (P=0.09). All autograft groups were found superior compared to their respective allograft treatment group (P<0.05). Solely allografts receiving combined treatment were found superior to untreated autografts (P<0.05). Conclusion: MSCs or FK506 treatment improved neurite outgrowth and when combined, this resulted in significant synergistic neurite extension in both autografts and allografts in comparable patterns. Schematic overview of 3D compartmented cell culture system for isolated evaluation of treatment with MSCs and local FK506 in vitro. A 3.5 mm autograft or allograft with or without undifferentiated MSC seeding is attached to a DRG. DRG-nerve graft constructs are placed through a silicone isolator in the middle of a 24-wells plate to isolate the DRG from the nerve graft. FK506 containing media was added to the nerve graft side.
QS3: Influence Of Nonsyndromic Bicoronal Synostosis And Syndromic Influences On And Periorbital Malformation
Alperovich, Michael , Persing, John A. , Lu, Xiaona , Forte, Antonio J. , Alonso, Nivaldo

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 27, 2021 | Volume: 9 | Issue: 7S | Pages: 26-27

10.1097/01.gox.0000770068.53559.0d Get It

Background Oculo-orbital disproportion in patients with craniosynostosis have similarities and dissimilarities between syndromic and nonsyndromic cases. We hypothesize these two conditions have specific individual influences as it relates to development of the orbital and periorbital skeletons. Method A total of 133 preoperative CT scans (nonsyndromic bicoronal synostosis, n=38; Apert syndrome bicoronal synostosis subtype, n=33; Crouzon syndrome bicoronal synostosis subtype, n=10; controls, n=52) were included. Craniometric and volumetric analyses related to the orbit and periorbital anatomy were performed. Results The orbital cavity volume is mildly restricted in nonsyndromic bicoronal synostosis (7%, p=0.147), but more so in Apert and Crouzon syndromes, 17% (p=0.002) and 21% (p=0.005), respectively. The sphenoid side angle in Apert syndrome is wider than when compared to Crouzon syndrome (p=0.043). The ethmoid side angle in Apert patients however is narrower (p=0.066) than that in Crouzon patients. Maxilla anteroposterior length is more restricted in Apert syndrome than Crouzon syndrome (21%, p=0.003) and nonsyndromic cases (26%, p<0.001). The posterior nasal spine position is retruded in Crouzon syndrome (39%, p<0.001), yet the anterior nasal spine position is similar in Apert and Crouzon syndromes. Conclusion Orbit and periorbital malformation in syndromic craniosynostosis is likely the combined influence of syndromic influences and premature suture fusion. Apert syndrome expands the anteriorly contoured lateral orbital wall associated with bicoronal synostosis, while Crouzon syndrome has more infraorbital rim retrusion, resulting in more severe exorbitism. Apert syndrome develops maxillary hypoplasia, in addition to the maxillary retrusion, observed in Crouzon syndrome and nonsyndromic bicoronal synostosis patients.